77 related articles for article (PubMed ID: 38408959)
21. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
22. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
23. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
24. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
25. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
Patzak MS; Kari V; Patil S; Hamdan FH; Goetze RG; Brunner M; Gaedcke J; Kitz J; Jodrell DI; Richards FM; Pilarsky C; Gruetzmann R; Rümmele P; Knösel T; Hessmann E; Ellenrieder V; Johnsen SA; Neesse A
EBioMedicine; 2019 Feb; 40():394-405. PubMed ID: 30709769
[TBL] [Abstract][Full Text] [Related]
26. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway.
Wang Y; Qin C; Zhao B; Li Z; Li T; Yang X; Zhao Y; Wang W
J Transl Med; 2023 Mar; 21(1):201. PubMed ID: 36932397
[TBL] [Abstract][Full Text] [Related]
27. Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis.
Yin L; Zhang J; Sun Y
Neoplasia; 2022 Dec; 34():100839. PubMed ID: 36240645
[TBL] [Abstract][Full Text] [Related]
28. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
Gu J; Huang W; Wang X; Zhang J; Tao T; Zheng Y; Liu S; Yang J; Chen ZS; Cai CY; Li J; Wang H; Fan Y
Mol Cancer; 2022 May; 21(1):112. PubMed ID: 35538494
[TBL] [Abstract][Full Text] [Related]
29. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
30. Egr‑1 inhibits colon cancer cell proliferation, migration and invasion via regulating CDKL1 at the transcriptional level.
Shao S; Ju M; Lei J; Lu X; Li H; Wang D; Xia C
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34165179
[TBL] [Abstract][Full Text] [Related]
31. The Role of the Transcription Factor EGR1 in Cancer.
Wang B; Guo H; Yu H; Chen Y; Xu H; Zhao G
Front Oncol; 2021; 11():642547. PubMed ID: 33842351
[TBL] [Abstract][Full Text] [Related]
32. EGR1 promotes stemness and predicts a poor outcome of uterine cervical cancer by inducing SOX9 expression.
Zhao J; Li H; Yuan M
Genes Genomics; 2021 May; 43(5):459-470. PubMed ID: 33687657
[TBL] [Abstract][Full Text] [Related]
33. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer.
Ma Z; Gao X; Shuai Y; Wu X; Yan Y; Xing X; Ji J
Cell Prolif; 2021 Jan; 54(1):e12922. PubMed ID: 33145887
[TBL] [Abstract][Full Text] [Related]
34. Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
El-Mahdy HA; El-Husseiny AA; Kandil YI; Gamal El-Din AM
Life Sci; 2020 Dec; 262():118518. PubMed ID: 33011221
[TBL] [Abstract][Full Text] [Related]
35. ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance.
Muriithi W; Macharia LW; Heming CP; Echevarria JL; Nyachieo A; Filho PN; Neto VM
Cancer Biol Med; 2020 May; 17(2):253-269. PubMed ID: 32587767
[TBL] [Abstract][Full Text] [Related]
36. A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells.
Ma S; Cheng J; Wang H; Ding N; Zhou F; Ji R; Zhu L; Zhu C; Pan Y
Carcinogenesis; 2021 Feb; 42(1):93-104. PubMed ID: 32531042
[TBL] [Abstract][Full Text] [Related]
37. Transcription factor EGR-1 transactivates the MMP1 gene promoter in response to TNFα in HaCaT keratinocytes.
Yeo H; Lee JY; Kim J; Ahn SS; Jeong JY; Choi JH; Lee YH; Shin SY
BMB Rep; 2020 Jun; 53(6):323-328. PubMed ID: 32317080
[TBL] [Abstract][Full Text] [Related]
38. Friend or foe, the role of EGR-1 in cancer.
Li TT; Liu MR; Pei DS
Med Oncol; 2019 Nov; 37(1):7. PubMed ID: 31748910
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
40. Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer.
Feng YH; Su YC; Lin SF; Lin PR; Wu CL; Tung CL; Li CF; Shieh GS; Shiau AL
BMC Cancer; 2019 Aug; 19(1):791. PubMed ID: 31399076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
